Genentech/Curis Hedgehog Inhibitor Gets Unclear Results In Ovarian Cancer Maintenance Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Roche/Genentech will "make a portfolio decision" on development of the novel Hedgehog inhibitor GDC-0449 in advanced ovarian cancer after further analyses of Phase II data, partner Curis said Aug. 9. Early analyses of top-line data "warrant additional investigation to clarify and interpret potential clinical activity," the company said